The purpose of this study is to see whether applying povidone iodine (PVI) to the noses of patients undergoing lower extremity (leg, ankle, or foot) orthopedic fixation procedures of high-energy lower extremity fractures (HELEF) will decrease the patients' risk of surgical site infections (SSI), particularly those caused by Staphylococcus aureus. THIS STUDY IS ENROLLING BY INVITATION ONLY

Low dose radiation in the treatment of benign diseases, including musculoskeletal disorders such as arthritis, is a standard clinical practice commonly utilized in some practices in the United States and even more commonly utilized in countries in Europe. This study will evaluate patients' pain and quality of life responses to this standard treatment through the use of surveys before and after their treatment for arthritis in our facilities.THIS STUDY IS ENROLLING BY INVITATION ONLY - Surveys and chart review will be performed within hospital clinics at IU Health for patients receiving LDRT for osteoarthritis. Some patients may be referred by other physicians or hear from word of mouth about this study. Patients will be seen in clinic during routine consultation appointments, and the study will be explained to them then. We will also email potential referring providers to let them know about the study using the provided email template.After consenting to the study, they will fill out pain score and quality of life surveys before and after undergoing the standard treatment with LDRT.

This Phase II study aims to evaluate the efficacy and safety of the combination of JSB462 (also known as luxdegalutamide) at 100 mg and 300 mg QD doses + lutetium (177Lu) vipivotide tetraxetan (hereafter referred as AAA617) compared with AAA617 (control) in participants with metastatic Castration Resistant Prostate Cancer (mCRPC) with prior exposure to at least 1 Androgen Receptor Pathway Inhibitor (ARPI) and 0-2 taxane regimens and to select the recommended dose of the combination for phase III. Towards that end, the totality of the efficacy, safety, tolerability and pharmacokinetic (PK) data from participants randomized in the study will be evaluated.Interested in participating? For more information about this research study or other cancer-related clinical trials at IU Simon Comprehensive Cancer Center, please contact:IU Clinical Trials Office Email: iutrials@iu.edu Phone: (317) 278-5632

Over the past 10 years, new medication options have been approved for patients with IBD who did not respond to anti-TNF treatments. However, data is still limited for how these new medications work.   This study may provide researchers with valuable information about the continued use of these medications. The purpose of this study is to compare the effectiveness and safety of these newer IBD medications. COMPARE is a multi-center, observational cohort study that includes both prospective and retrospective components and two patient population cohorts-Crohn's disease (CD) and ulcerative colitis (UC). THIS STUDY IS ENROLLING BY INVITATION ONLY - Potential participants with CD and 550 with UC or IBD-U whose disease is refractory to anti-TNF therapy will be identified and contact by the research team about study participation.

This multicenter, randomized, parallel-arm, double-blind, placebo-controlled Phase 3 umbrella- type master protocol aims to create a framework for simultaneously evaluating the safety and efficacy of multiple pharmacologic agents (interventions) for the treatment of high-risk metabolic dysfunction-associated steatotic liver disease.THIS STUDY IS ENROLLING BY INVITATION ONLY - The study team will identify and invite potential participants with MASLD who may also have been diagnosed with type 2 diabetes mellitus (T2DM) to enroll in the study.

This phase II MyeloMATCH treatment trial compares the usual treatment of azacitidine and venetoclax to the combination treatment of azacitidine, venetoclax and gilteritinib in treating older and unfit patients with acute myeloid leukemia and FLT3 mutations. Azacitidine is a drug that is absorbed into DNA and leads to the activation of cancer suppressor genes, which are genes that help control cell growth. Venetoclax is in a class of medications called B-cell lymphoma-2 (BCL-2) inhibitors. It may stop the growth of cancer cells by blocking Bcl-2, a protein needed for cancer cell survival. Gilteritinib is in a class of medications called kinase inhibitors. It works by blocking the action of a certain naturally occurring substance that may be needed to help cancer cells multiply. This study may help doctors find out if these different approaches are better than the usual approaches. To decide if they are better, the study doctors are looking to see if the study drugs lead to a higher percentage of patients achieving a deeper remission compared to the usual approach.Interested in participating? For more information about this research study or other cancer-related clinical trials at IU Simon Comprehensive Cancer Center, please contact:IU Clinical Trials Office Email: iutrials@iu.edu Phone: (317) 278-5632

TNG462-C102 is a Phase 1/2, open-label, multicenter study designed to determine the safety, tolerability, PK, PD, and preliminary antineoplastic activity of oral TNG462 in combination with the following agents: RMC-6236, RMC-9805, mFOLFIRINOX, or gemcitabine/nab-paclitaxel. Overall, the study comprises a dose escalation phase and a dose expansion phase.Interested in participating? For more information about this research study or other cancer-related clinical trials at IU Simon Comprehensive Cancer Center, please contact:IU Clinical Trials Office Email: iutrials@iu.edu Phone: (317) 278-5632